文献速递核素与放射性配体治疗肿瘤 PET/CT

使用循环转录本分析监测PRRT神经内分泌肿瘤反应:NETest研究

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-12-14

该前瞻性研究纳入三个独立队列共157例接受177Lu-PRRT的胃肠胰及肺神经内分泌肿瘤患者,评估NETest作为RECIST替代标志物的价值及其与PPQ预测的相关性。结果显示NETest监测准确率为98%,PPQ预测准确率为97%,NETest下降可识别应答者并与PPQ预测高度相关,而CgA无信息价值。

要点

  • NETest监测PRRT疗效准确率达98%(119/122),可作为RECIST的替代标志物。
  • PPQ预测PRRT应答准确率为97%(118/122),阳性预测准确率99%,阴性预测准确率93%。
  • 随访NETest稳定(<40)vs进展(>40)与mPFS显著相关(未达到 vs 10个月;HR 0.04)。

核心结论

  • PPQ预测PRRT应答准确率为97%,NETest准确监测PRRT反应,是PRRT放射学反应的有效替代标志物。
  • NETest下降识别应答者,并与治疗前PPQ应答预测因子相关(>97%)。
  • CgA无信息价值。

研究设计与样本

  • 前瞻性评估三个独立接受177Lu-PRRT治疗的胃肠胰神经内分泌肿瘤及肺队列:意大利Meldola(n=72)、德国Bad-Berka(n=44)、荷兰Rotterdam(n=41)。
  • 治疗反应按RECIST1.1分为应答者(稳定、部分缓解和完全缓解)与非应答者。
  • 血样采集时间:PRRT前、每周期前及随访(2-12个月)。
  • PPQ(阳性/阴性)和NETest(0-100评分)通过PCR检测,NETest稳定<40、进展>40;CgA(ELISA)作为对照。
  • 样本去标识化,检测和分析盲法;采用Kaplan-Meier生存分析和标准统计学方法。

主要发现

  • 157例中122例可评估;RECIST稳定或缓解者占67%,进展者占33%。
  • NETest在RECIST应答者中显著下降(-47±3%),在非应答者中持续升高(+79±19%)(p<0.0005),组间比较p<0.0001。
  • NETest监测准确率为98%(119/122)。
  • 随访NETest进展(>40)vs稳定(<40)与mPFS显著相关(未达到 vs 10个月;HR 0.04,95%CI 0.02-0.07)。
  • PPQ应答预测准确118例(97%),阳性预测准确率99%,阴性预测准确率93%;NETest在PPQ预测应答者中显著下降(-46±3%),在PPQ预测非应答者中持续升高或增加(+75±19%)(p<0.0001)。

关键数值与推荐

  • NETest评分0-100,稳定<40,进展>40。
  • RECIST1.1应答者包括稳定、部分缓解和完全缓解。
  • NETest监测准确率98%(119/122);PPQ预测准确率97%(118/122),阳性预测准确率99%,阴性预测准确率93%。
  • 随访NETest进展vs稳定与mPFS相关:HR 0.04(95%CI 0.02-0.07);PPQ预测分层下HR 0.06(95%CI 0.03-0.12)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Peptide receptor radionuclide therapy (PRRT) is effective for metastatic/inoperable neuroendocrine tumors (NETs). Imaging response assessment is usually efficient subsequent to treatment completion. Blood biomarkers such as PRRT Predictive Quotient (PPQ) and NETest are effective in real-time. PPQ predicts PRRT efficacy; NETest monitors disease. We prospectively evaluated: (1) NETest as a surrogate biomarker for RECIST; (2) the correlation of NETest levels with PPQ prediction. METHODS: Three independent 177Lu-PRRT-treated GEP-NET and lung cohorts (Meldola, Italy: n = 72; Bad-Berka, Germany: n = 44; Rotterdam, Netherlands: n = 41). Treatment response: RECIST1.1 (responder (stable, partial, and complete response) vs non-responder). Blood sampling: pre-PRRT, before each cycle and follow-up (2-12 months). PPQ (positive/negative) and NETest (0-100 score) by PCR. Stable < 40; progressive > 40). CgA (ELISA) as comparator. Samples de-identified, measurement and analyses blinded. Kaplan-Meier survival and standard statistics. RESULTS: One hundred twenty-two of the 157 were evaluable. RECIST stabilization or response in 67%; 33% progressed. NETest significantly (p < 0.0001) decreased in RECIST "responders" (- 47 ± 3%); in "non-responders," it remained increased (+ 79 ± 19%) (p < 0.0005). NETest monitoring accuracy was 98% (119/122). Follow-up levels > 40 (progressive) vs stable (< 40) significantly correlated with mPFS (not reached vs. 10 months; HR 0.04 (95%CI, 0.02-0.07). PPQ response prediction was accurate in 118 (97%) with a 99% accurate positive and 93% accurate negative prediction. NETest significantly (p < 0.0001) decreased in PPQ-predicted responders (- 46 ± 3%) and remained elevated or increased in PPQ-predicted non-responders (+ 75 ± 19%). Follow-up NETest categories stable vs progressive significantly correlated with PPQ prediction and mPFS (not reached vs. 10 months; HR 0.06 (95%CI, 0.03-0.12). CgA did not reflect PRRT treatment: in RECIST responders decrease in 38% and in non-responders 56% (p = NS). CONCLUSIONS: PPQ predicts PRRT response in 97%. NETest accurately monitors PRRT response and is an effective surrogate marker of PRRT radiological response. NETest decrease identified responders and correlated (> 97%) with the pretreatment PPQ response predictor. CgA was non-informative.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bodei L, Kidd MS, Singh A, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. Eur J Nucl Med Mol Imaging. 2019. PMID: 31838581. doi:10.1007/s00259-019-04601-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。